Prematüre retinopatisinde intravitreal anti-VEGF tedavisi
نویسندگان
چکیده
منابع مشابه
Vitreous Inflammation Associated with Intravitreal Anti-VEGF Pharmacotherapy
Vascular endothelial growth factor (VEGF) is a potent promoter of angiogenesis involved in a wide variety of physiologic processes. Intravitreal injections targeting VEGF have transformed the treatment of neovascular retinal diseases. Currently, there are four anti-VEGF agents in use: bevacizumab, ranibizumab, pegaptanib, and aflibercept. The success and frequency of anti-VEGF therapy have made...
متن کاملA calipers-free intravitreal anti-VEGF injection technique.
Dear Editor, Intravitreal injection of drugs such as anti-vascular endothelial growth factor (anti-VEGF) agents and corticosteroids has shown encouraging results in the treatment of many ocular diseases. In developed countries, this type of injection is probably the most frequently performed vitreoretinal procedure. However, it has the potential for serious complications, such as endophthalmiti...
متن کاملAnti-VEGF effects of intravitreal erythropoietin in early diabetic retinopathy.
In the present study, a single intravitreal erythropoietin (EPO) to diabetic rats produced therapeutic effects on blood-retinal barrier (BRB) function and neuronal survival at different time courses of retinopathy. In parallel, the hypoxia-inducible factor 1 alpha (HIF-1 alpha) pathway has been quantitatively studied, including VEGF-A, endogenous EPO, EPO receptor (EpoR), prolyl hydroxylases (P...
متن کاملThe remote effects of intravitreal anti-VEGF therapy
Objective: To study the effects of intravitreal anti-Vascular Endothelial Growth Factor (VEGF) therapy with Avastin for wet Age-Related Macular Degeneration (AMD) on Benign Prostatic Hyperplasia (BPH)-related symptoms. Methods: An exploratory trial was conducted from August 1, 2013 to February 1, 2014, that included 14 male patients previously diagnosed with BPH, who were aged between 59 and 69...
متن کاملObservation of total VEGF level in hyperglycemic mouse eyes after intravitreal injection of the novel anti-VEGF drug conbercept
PURPOSE Conbercept (KH902), a novel recombinant, soluble vascular endothelial growth factor (VEGF) receptor-IgG fusion protein, has been developed as a new drug for ocular neovascularization and macular edema. The present study aims to clarify the changes in conbercept levels, VEGF, and intraocular pressure (IOP) after the intravitreal injection of conbercept into diabetic mouse eyes. METHODS...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Zeynep Kamil Tıp Bülteni
سال: 2015
ISSN: 2148-4864,1300-7971
DOI: 10.16948/zktb.34843